BlackRock Institutional Trust’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

BlackRock Institutional Trust’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.81M	Buy	312,491 +79,090	+34%	+$1.03M	﹤0.01%	2742
2016 Q3	$3.04M	Buy	233,401 +92,225	+65%	+$1.22M	﹤0.01%	2888
2016 Q2	$1.96M	Buy	141,176 +11,443	+9%	+$168K	﹤0.01%	3047
2016 Q1	$1.97M	Sell	129,733 -1,228	-0.9%	-$18.8K	﹤0.01%	3053
2015 Q4	$2.48M	Buy	130,961 +5,426	+4%	+$104K	﹤0.01%	3030
2015 Q3	$2.38M	Buy	125,535 +36,827	+42%	+$918K	﹤0.01%	3058
2015 Q2	$2.29M	Buy	+88,708	New	+$2.52M	﹤0.01%	3067
2015 Q1	–	Sell	-7,887	Closed	-$304K	–	3910
2014 Q4	$304K	Sell	7,887 -2	-0%	-$48	﹤0.01%	3592
2014 Q3	$192K	Hold	7,889	–	–	﹤0.01%	3612
2014 Q2	$188K	Hold	7,889	–	–	﹤0.01%	3707
2014 Q1	$292K	Hold	7,889	–	–	﹤0.01%	3660
2013 Q4	$318K	Hold	7,889	–	–	﹤0.01%	3647
2013 Q3	$301K	Hold	7,889	–	–	﹤0.01%	3616
2013 Q2	$286K	Buy	+7,889	New	+$338K	﹤0.01%	3584

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

BlackRock Institutional Trust's PRTK Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Paratek Pharmaceuticals, Inc. (PRTK) stake by 34% in Q4 2016, buying an estimated $1.03M and bringing the position to 312,491 shares worth $4.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2742.

BlackRock Institutional Trust first reported a position in PRTK in Q2 2013 and has held it in 14 quarters since. 92 funds tracked by Wall St. Rank hold PRTK as of Q4 2016.

BlackRock Institutional Trust held 312,491 shares of Paratek Pharmaceuticals, Inc. worth $4.81M as of Q4 2016.
BlackRock Institutional Trust bought 79,090 Paratek Pharmaceuticals, Inc. shares in Q4 2016, an estimated $1.03M.
Paratek Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2742 holding.
BlackRock Institutional Trust first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and has held it in 14 quarters since.
92 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.